Search results: (10000)
News Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction
Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI) through sacubitril/valsartan reduces cardiovascular (CV) mortality and the risk of hospitalization for heart failure. The same benefit has also been demonstrated with the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), also known as gliflozins. A pre-specified sub-analysis of the EMPEROR-Reduced study evaluated whether the benefit of SGLT2i is also significant in patients treated with ARNI.
News Composition of the Intestinal Microbiota of Patients with IBS May Predetermine the Success of a Diet with Low Fermentable Carbohydrates
Some patients with irritable bowel syndrome may benefit from a diet low in fermentable carbohydrates, but the mechanism of this intervention is not yet satisfactorily explained. A study published in Gut focused on the relationship between the composition of the intestinal microbiota and clinical response to dietary intervention.
News Early Detection of Erectile Dysfunction in Men with Type 2 Diabetes
A retrospective study published last year identified predictors of erectile dysfunction in men with type 2 diabetes. The authors recommend screening patients with elevated uric acid levels, diabetes duration ≥ 49 months, and diabetic retinopathy.
News Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
In a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.
News Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or death from cardiovascular (CV) causes in the EMPEROR-Reduced study in patients with adequately treated heart failure with reduced left ventricular ejection fraction (HFrEF) compared to placebo, regardless of whether the patients had diabetes. A post hoc analysis of this study focused on another important question: how does the benefit of adding empagliflozin interact with the standard disease-modifying therapy for heart failure?
News Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023
In August 2022, the latest guidelines from the National Comprehensive Cancer Network (NCCN) concerning chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were published. Here we present the essential extract from these recommendations for diagnosing both diseases.
News Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is the angiotensin II receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan, which has shown to improve the prognosis of patients with HFrEF. A recently published study compared the initiation of ARNI or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in patients with HFrEF who were not previously treated with a RAAS inhibitor in real-world practice.
News Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS − What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?
Current treatment options for irritable bowel syndrome (IBS − irritable bowel syndrome) are relatively limited. This increases interest in complementary and alternative therapy options with plant preparations. One modality used to alleviate IBS symptoms is Aloe barbadensis Mill. The aim of a clinical study by Swedish researchers was to assess the effect of aloe on IBS symptoms compared to a control treatment with inulin.
News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.
News Incidence of Secondary Malignancies in CLL Patients on FCR Regimen in Central Europe
Chronic lymphocytic leukemia (CLL) represents the most common type of leukemia in Western countries with closely related incidence in Central European states. Since 2000, new therapeutic regimens have been explored and applied in an effort to improve patient prognosis, including the combination of fludarabine, cyclophosphamide, and rituximab (FCR). However, the development of new therapeutic regimens is also associated with concerns about the risk of secondary malignancies.
News Romiplostim Before Splenectomy in a Patient with ITP - Case Report
In the following case report from authors at a university hospital in Barcelona, the successful use of romiplostim as a second-line treatment before planned splenectomy in a patient with immune thrombocytopenia (ITP), liver cirrhosis, and iatrogenic Cushing's syndrome is demonstrated.
News What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?
Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD). What is the efficacy and safety of sorafenib in this patient population, and does it differ from patients with liver cancers caused by viral infection or alcohol abuse? This intrigued a team of researchers from Melbourne, Australia.
News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis
Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.
News Specific treatment of pulmonary involvement in patients with AAT deficiency − why, how, and for whom?
For patients with emphysema and decreased lung function due to alpha-1-antitrypsin deficiency (AATD), there is an approved specific treatment which involves the i.v. administration of alpha-1-antitrypsin (AAT) derived from human plasma. This augmentation therapy slows the loss of lung tissue density. Its effects and impact on the frequency and duration of exacerbations, quality of life, lung functions, and patient mortality are less clear.
News Diagnosis of AAT Deficiency According to Italian Recommendations and a Clear Algorithm for Practice
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that primarily affects the lungs and liver. It is considered a rare disease, but it is also significantly underdiagnosed. Given the availability of specific treatment, which involves the administration of purified alpha-1 antitrypsin (AAT) derived from human plasma in patients with COPD due to AATD, identifying these patients is crucial. We summarize the recently issued Italian recommendations for the diagnosis of AATD and place them in the context of Czech standards.